Abstracts

509 – Myeloid Targeted and Enhanced Endosomal Escapable LNPs Improve Latent HIV-1 Elimination Efficacy

Background A cure for HIV remains elusive as the excision of latent proviral DNA by adenovirus-based therapeutic systems has failed to date due to vector immunogenicity and limited targeting to viral reservoirs. In contrast, lipid nanoparticles (LNPs) are promising for targeting viral reservoirs, offering greater cargo-carrying capacity and reduced immune responses. However, limitations in endosomal…

556 – Reservoir-Harboring T-Cell Clones Have a Cytotoxic Immunophenotype That May Affect HIV Inducibility

Background The HIV reservoir is enriched for clonal CD4+ T-cells harboring intact proviruses after years of antiretroviral therapy (ART). In this study, we characterize the immunophenotypes of ‘authentic reservoir-harboring clones’ (ARCs) isolated and propagated from people living with HIV (PLWH) and aim to understand the contribution of these profiles to persistence. Methods Individual ARCs from…

526 – Nonsuppressible HIV Viremia May Harbor Replication-Incompetent Viruses With 5′ Leader Deletions

Background Individuals with nonsuppressible viremia (NSV) have persistent low-level viremia despite ART adherence and lack of drug resistance. A subset was reported to harbor deletions in the 5′ end of the HIV-1 genome, specifically within the 5′ PSI packaging element. We have previously reported three individuals with NSV and plasma variants harboring deletions in the…

549 – Plasma Cytokines and NF-κB Signaling Drive Transcriptomic Diversity in CD4+ T Cells From PWH on ART

Background Antiretroviral therapy (ART) is not a cure, and HIV rapidly rebounds upon ART interruption. Furthermore, people with HIV (PWH) on ART have elevated immune activation and inflammation which has been associated with increased risk of aging-associated diseases which may be driven by this viral persistence.  Methods To identify the potential mechanisms by which HIV…

505 – Sustained Post-Rebound HIV Remission With Enhanced T-Cell Immunity After LS-bNAbs: A Case Report

Background Non-human primate (NHP) models of HIV cure using HIV-specific broadly neutralising antibodies (bNAbs) describe viral control after an initial period of rebound, attributable to HIV-specific T cell responses – a ‘vaccinal effect’. There are examples of viral control after bNAbs in human studies, but no cases of post-bNAb viral rebound followed by sustained suppression,…

508 – Maximizing Benefits to Participants in Analytic Treatment Interruption With Antibody Infusions

Background Analytic treatment interruption (ATI) studies utilizing broadly neutralizing antibody (bnAb) infusions are associated with delayed viral rebound if viruses found in the participants are sensitive to the bnAbs. Yet, viral sensitivity is typically evaluated only after the ATI has been conducted. For a future ATI that will enroll 35 participants from the RV254 Thai…